Señales en vivo de ENZ | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	114 913
Volumen promedio	109 219
Capitalización de mercado	53.79M
EPS	$0 ( 2024-03-19 )
Próxima fecha de ganancias	( $0 ) 2024-06-12
Last Dividend	$0.0470 ( 1995-06-29 )
Next Dividend	$0 ( N/A )
P/E	-2.23
ATR14	$0.00300 (0.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-23	Cannon Kara	Buy	150 000	Common Stock
2024-02-21	Cannon Kara	Buy	10 640	Common Stock
2024-02-21	Cannon Kara	Sell	5 823	Common Stock
2024-02-23	Eckert Patricia	Buy	75 000	Stock Option (to acquire shares of Common Stock)
2024-01-31	Pully Steven J	Buy	79 365	Common Stock

INSIDER POWER
88.55
Last 85 transactions
Buy: 4 325 861 \| Sell: 177 248

Volumen Correlación

Largo: 0.27 (neutral)

Corto: -0.56 (weak negative)

Signal:(51.331) Neutral

Enzo Biochem Inc Correlación

10 Correlaciones Más Positivas
YSAC	0.906
TSQ	0.849
HZN	0.841
DTC	0.828
CRD-A	0.819

10 Correlaciones Más Negativas
FPEI	-0.872
ASB-PE	-0.868
CUBB	-0.868
GL	-0.855
FLR	-0.852
NX	-0.843
MBI	-0.836
PQDI	-0.832
BGSF	-0.832
SPNT-PB	-0.825

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Enzo Biochem Inc Correlación - Moneda/Commodity

-0.07
( neutral )

-0.35
( neutral )

0.00
( neutral )

0.19
( neutral )

Enzo Biochem Inc Finanzas

Annual	2023
Ingresos:	$31.06M
Beneficio Bruto:	$11.57M (37.24 %)
EPS:	$-1.270

FY	2023
Ingresos:	$31.06M
Beneficio Bruto:	$11.57M (37.24 %)
EPS:	$-1.270

FY	2022
Ingresos:	$107.07M
Beneficio Bruto:	$41.97M (39.20 %)
EPS:	$-0.460

FY	2021
Ingresos:	$117.73M
Beneficio Bruto:	$53.58M (45.51 %)
EPS:	$0.160

Financial Reports:

No articles found.

Enzo Biochem Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Enzo Biochem Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 5.02 - average (34.50%) | Divividend Growth Potential Score: 0.366 - No dividend growth expected in the near future

Information

First Dividend	$0.0470	1995-06-29
Last Dividend	$0.0470	1995-06-29
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.0470	--
Avg. Dividend % Per Year	0.00%	--
Score	0.82	--
Div. Sustainability Score	5.02
Div.Growth Potential Score	0.366
Div. Directional Score	2.69	--

Next Divdend (Est)
(2024-04-27)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.82

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
1995	$0.0470	0.58%
1996	$0	0.00%
1997	$0	0.00%
1998	$0	0.00%
1999	$0	0.00%
2000	$0	0.00%
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$0	0.00%
2005	$0	0.00%
2006	$0	0.00%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	2.58	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.333	1.200	10.00	10.00	[0 - 0.3]
returnOnEquityTTM	0.545	1.500	5.06	7.59	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.20	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.78	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.58	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0444	-1.500	9.26	-10.00	[0 - 0.6]
interestCoverageTTM	33.77	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.879	2.00	-0.293	-0.586	[0 - 30]
freeCashFlowPerShareTTM	-0.909	2.00	-0.455	-0.909	[0 - 20]
debtEquityRatioTTM	0.0621	-1.500	9.75	-10.00	[0 - 2.5]
grossProfitMarginTTM	-1.203	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.348	1.000	-8.96	-8.96	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-10.10	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.129	0.800	-2.47	-1.977	[0.5 - 2]
Total Score				5.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	1.605	1.000	9.94	0	[1 - 100]
returnOnEquityTTM	0.545	2.50	6.82	7.59	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.909	2.00	-0.303	-0.909	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.879	2.00	-0.293	-0.586	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.00912	1.500	-3.39	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-3.47	1.000	-10.00	0	[0.1 - 0.5]
Total Score				0.366

Enzo Biochem Inc

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.